Date: 2015-04-09
Type of information: Collaboration agreement
Compound:
Company: Cortendo (Sweden) National Organization for Rare Disorders (NORD)®
Therapeutic area: Rare diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On April 8, 2015, Cortendo, a global biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and the National Organization for Rare Disorders (NORD)®, a leading, independent nonprofit organization committed to the identification, treatment and cure of rare diseases announced that Cortendo has joined NORD’s Corporate Council.The NORD Corporate Council is composed of a select group of leading companies committed to helping people with rare diseases. The Council provides a unique opportunity for interaction with the rare disease community, including patient advocacy organizations, and enables companies to discuss emerging trends with top experts in the worldwide rare disease effort. Members include pharmaceutical, biotechnology, medical device and other companies engaged in the aspects of health care for the rare disease/orphan product community. Membership supports NORD\'s programs of education, advocacy, research and service. “Cortendo is proud to announce joining NORD’s Corporate Council today, which marks National Cushing’s Syndrome Awareness Day,” said Matthew Pauls, president and chief executive officer of Cortendo. “Our partnership with NORD reinforces Cortendo’s commitment to advancing research and development efforts that may improve the lives of people with rare diseases, including our currently recruiting Phase 3 trial of the investigational compound COR-003 (levoketoconazole), which is being studied in Cushing\'s Syndrome.”
Financial terms:
Latest news:
